Dividends Novo Nordisk’s Pipeline Gains Traction as Zenagamtide Data and CagriSema Filing Drive Investor Focus
The Danish pharmaceutical heavyweight is navigating a turbulent stretch, with its stock languishing roughly 46% below the June 2025 peak of €70.13. But a flurry of clinical updates and a...